Atossa Therapeutics Files 8-K Report
Ticker: ATOS · Form: 8-K · Filed: Mar 12, 2025 · CIK: 1488039
| Field | Detail |
|---|---|
| Company | Atossa Therapeutics, INC. (ATOS) |
| Form Type | 8-K |
| Filed Date | Mar 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: ATOS
TL;DR
ATOS filed an 8-K. Check for updates on financials/events.
AI Summary
On March 11, 2025, Atossa Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing signals that Atossa Therapeutics is providing updates to the SEC, which could include material information relevant to investors. Investors should review the full filing for details on any disclosed events or financial statements.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific material events or financial data that would inherently increase risk.
Key Players & Entities
- ATOSSA THERAPEUTICS, INC. (company) — Registrant
- 0000950170-25-037634 (filing_id) — Accession Number
- 20250311 (date) — Report Date
- 20250312 (date) — Filing Date
- 206.588.0256 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events.
When was this 8-K report filed?
The report was filed on March 12, 2025.
What is the exact name of the company filing the report?
The exact name of the company is Atossa Therapeutics, Inc.
In which state was Atossa Therapeutics, Inc. incorporated?
Atossa Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address of Atossa Therapeutics, Inc.?
The address of the Principal Executive Offices is 10202 5th Avenue NE, Suite 200, Seattle, Washington 98125.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 12, 2025 regarding ATOSSA THERAPEUTICS, INC. (ATOS).